|
|
PennyPerformers.com: "Penny Stocks that Perform" picks are: CAMP, CYTR, UNDT
Jun 17, 2009 (M2 PRESSWIRE via COMTEX) --
Jun 17, 2009 Pennyperformers.com "Penny Stocks that Perform" picks are: CalAmp Corp. (NASDAQ: CAMP), CytRx Corporation (NASDAQ: CYTR), Universal Detection Technology (OTCBB: UNDT)
Sign-up for our FREE Stock Alerts AND NEWSLETTER at www.pennyperformers.com
Jun 17, 2009 -- CalAmp Corp. (NASDAQ: CAMP), a leading provider of wireless products, services and solutions, today announced it has entered into an exclusive agreement with EADS Defence & Security to supply a customized version of its WiMAX-based Sentry 4G(TM) Wireless IP Router, a new rugged broadband communications and networking platform for mission-critical broadband communication applications. The custom high-power mobile data terminal will be marketed under the EADS Defence & Security brand name to address customers in the defense and public safety markets outside the United States and Canada.
CalAmp's Sentry 4G provides high-speed, long-range broadband wireless connectivity based on IEEE 802.16e-2005 (mobile WiMAX) technology and also supports an embedded Wi-Fi module as well as GPS.
The targeted market will be defense and security customers where licensed 2.5 GHz frequencies are available for mobile broadband wireless applications. Applications for the device include video surveillance and other visual multimedia applications providing officers with increased situational awareness through a WiMAX network overlay to existing mission-critical Professional Mobile Radio (PMR) networks.
"We were looking to extend the EADS Defence & Security portfolio in order to better respond to customer requirements for wireless broadband connectivity," said Dirk Borchardt, Head of Security and Communication Solutions in EADS Defence & Security. "CalAmp is a leader in wireless data communication and understands the unique needs of mission-critical public safety communications. We selected CalAmp's Sentry 4G as an ideal platform to address the broadband wireless connectivity needs of our customers and are pleased to welcome CalAmp as a trusted partner."
"Video Surveillance is just one of the applications that highlight the need for mobile, high-speed, long-range broadband wireless connectivity in the defense and security markets," commented Michael Burdiek, Chief Operating Officer of CalAmp. "We are proud to be selected by EADS Defence & Security as supplier of the broadband wireless subscriber units for EADS customers outside the U.S. and Canada. EADS is a global leader for mission-critical communications systems and we look forward to contributing our wireless technology expertise to a long-term alliance with EADS."
About CalAmp Corp.
CalAmp provides wireless communications solutions that enable anytime/anywhere access to critical data and content. The Company serves customers in the public safety, industrial monitoring and controls, mobile resource management, public utilities and direct broadcast satellite markets. The Company's products are marketed under the CalAmp, Dataradio, SmartLink, Aercept, LandCell and Omega trade names.
About EADS Defence & Security
EADS Defence & Security is a world leading provider of mission-critical communication and Command & Control solutions through its line of business Security and Communication Solutions. Its portfolio ranges from sensors and secure networks through missiles to aircraft and UAVs as well as global security, service and support solutions. In 2008, DS - with around 23,000 employees - achieved revenues of EUR 5.7 billion. EADS is a global leader in aerospace, defence and related services. In 2008, EADS generated revenues of EUR 43.3 billion and employed a workforce of about 118,000.
Jun 17, 2009 -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that tamibarotene, currently under evaluation in a U.S. registration trial as a third-line treatment for acute promyelocytic leukemia (APL), showed statistically significant anti-tumor activity in human myeloma cells transplanted into animals. Multiple myeloma is an incurable malignant tumor of the plasma cells of bone marrow. Results of the trial were published in the June 2009 peer-reviewed journal Cancer Science (Volume 100, No. 6, Pages 1137-1143).
"These results support our contention that tamibarotene's mechanism of action may provide broad commercial potential as a therapeutic treatment beyond APL to other cancers such as multiple myeloma," said Steven A. Kriegsman, CytRx President and CEO. "Despite advances in therapies that improve the quality of life and length of survival, many multiple myeloma patients experience severe side effects from current therapies, prompting the need for additional therapies."
"We are evaluating opportunities for a Phase 2 clinical program with tamibarotene as a multiple myeloma therapy, as well as investigating partnership prospects for developing and commercializing tamibarotene in the U.S. for both multiple myeloma and APL," he added.
CytRx has the right to develop tamibarotene as a treatment for multiple myeloma in Europe, and has the option to expand its license for the use of tamibarotene for multiple myeloma and certain other oncology applications in the U.S. Tamibarotene is currently approved for relapsed or refractory treatment of APL in Japan.
The animal trial, conducted by an independent third party in Japan, was designed to evaluate the activity of tamibarotene as a multiple myeloma treatment alone and in combination with a glucocorticoid, a commonly prescribed treatment for this disease. Five different human myeloma cell lines were treated with tamibarotene alone, glucocorticoids alone, or tamibarotene + glucocorticoids in cell culture. Tamibarotene by itself inhibited the growth of these tumor cells two- to 10-fold more potently than all-trans retinoic acid (ATRA), a less specific relative of tamibarotene which has previously been shown to inhibit the growth of human myeloma cells. Importantly, the combination of tamibarotene with glucocorticoids was found to show markedly greater growth inhibition than either drug alone.
Human myeloma cells were then transplanted into mice with compromised immune systems to study the tumor growth-inhibitory effects of these drugs. Both tamibarotene and glucocorticoids by themselves reduced the rate of tumor growth. However, the combination of tamibarotene with glucocorticoids showed a synergistic interaction that resulted in markedly decreased tumor growth and increased survival compared with either drug alone. Trial investigators concluded that tamibarotene in this drug combination approach was among the most promising potential therapeutic regimens for multiple myeloma, especially in high-risk patients, and should be further investigated.
"Our drug tamibarotene is more stable and may have fewer adverse events than ATRA, with both drugs demonstrating the ability to force certain types of leukemia cells to cease growing uncontrollably and return to performing their normal functions - a process known as terminal differentiation," said Jack Barber Ph.D., CytRx's Chief Scientific Officer. "Multiple myeloma cells are thought to grow uncontrollably due in part to a growth factor called IL-6. Glucocorticoids are a potent inducer of cell death; however this benefit may be offset by their known activation of IL-6 activity. Tamibarotene has previously shown the ability to interfere with the normal functioning of IL-6, which could be the foundation for the anti-proliferative effects of tamibarotene in multiple myeloma, particularly in combination with glucocorticoids.
"We are delighted and encouraged by this proof of concept, which could ultimately increase the potential market for tamibarotene," added Dr. Barber.
About Multiple Myeloma
Multiple myeloma is the second most common hematologic malignancy in the U.S. According the National Cancer Institute, an estimated 20,580 new cases of multiple myeloma will be diagnosed in the U.S., and 10,580 multiple myeloma patient deaths will be recorded in 2009. According to industry leading researcher Mattson Jack Group, currently in the top seven markets (including the U.S., EU and Japan), the number of new cases each year is expected to total more than 43,500. The average five-year survival is 35 percent and the American Cancer Society found multiple myeloma to be the sixth deadliest cancer in terms of a mortality-to-incidence ratio.
Multiple myeloma is characterized by malignant plasma cells that form tumors in the bone marrow. These plasma cell tumors can spread throughout the bone marrow, thereby disrupting the production of red blood cells and platelets, which normally occur in the bone marrow. Excessive amounts of malignant plasma cells also may decrease the number of white blood cells, which are important in fighting off infections.
About Tamibarotene
Tamibarotene is an orally available, rationally designed, synthetic retinoid compound designed to potentially avoid toxic side effects by binding to its molecular target more selectively than all trans-retinoic acid (ATRA), the current first-line treatment for APL. A Special Protocol Assessment (SPA) is in place with the U.S. Food and Drug Administration (FDA) for a Phase 2 registration clinical trial, known as STAR-1, which is evaluating the efficacy and safety of tamibarotene as a third-line treatment for APL. The STAR-1 trial is ongoing and currently includes 30 clinical sites, 22 of which are in Europe, and one in Canada. CytRx believes that successful data from the STAR-1 trial and supporting studies, in conjunction with data from the Japanese clinical trials, will form the basis for a New Drug Application (NDA).
The FDA has granted Orphan Drug Designation and Fast Track Designation for the use of tamibarotene in patients with relapsed or refractory APL following treatment with all-trans retinoic acid (ATRA) and arsenic trioxide. The efficacy of orally administered tamibarotene was demonstrated in two Phase 2 studies conducted in Japan in a total of 63 Japanese subjects with APL. The overall complete response rate in these subjects was 60%. In subjects experiencing their first relapse, the overall complete response rate was 81%. In addition to multiple myeloma, CytRx also retains an option to expand its licenses for the use of tamibarotene in other fields in oncology, including myelodysplastic syndrome and certain solid tumors in the U.S., and myelodysplastic syndromes and solid tumors other than hepatocellular carcinoma in Europe.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration study for the treatment of acute promyelocytic leukemia (APL). In addition, CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. CytRx also maintains a 45% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ:RXII).
Jun 16, 2009 -- Universal Detection Technology (OTCBB: UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-terrorism consulting and training services, today announced that it has applied for CAGE and NSN Stock numbers for its biological detection equipment. The numbers will facilitate the sales of the items to the U.S. Department of Defense (DOD) and the North Atlantic Treaty Organization (NATO).
The DOD, which spends 75 cents of every federal government contracting dollar, has its own government contractor classification system. The Commercial And Government Entity, or CAGE, code is a five-character ID number that identifies government contractors. CAGE codes are an important part of winning federal government contracts.
The NATO Stock number (NSN) is a classification code that NATO assigns to its defense inventory. NATO affiliated countries follow common standards and techniques to assign NSNs to items of supply in their defense inventory. The National Codification Bureau (NCB) within each country centrally assigns their national NSNs. The assignment of an NSN fixes the identity of each distinctive item of supply.
"The obtaining of the CAGE and NSN codes will allow us to increase our sales to the U.S. DOD as well as the NATO affiliated countries," said Mr. Jacques Tizabi, UNDT's Chief Executive Officer. "We are planning a dedicated marketing effort for our biological detection equipment in Europe," he added.
About Universal Detection Technology
Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The Company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, the Company, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The Company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems, and antimicrobial products.
About PennyPerformers.com
PennyPerformers.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.
Penny Performers email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Penny Performers Report home page at www.PennyPerformers.com and select the "join now" button.
Join us at www.PennyPerformers.com for a complimentary subscription to the most exciting online financial newsletter on the market.
Disclaimer: Verify all claims and do your own due diligence. PennyPerformers.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyPerformers.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. PennyPerformers.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), PennyPerformers.com is owned and operated by PennyPerformers.com. Neither PennyPerformers.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since PennyPerformers.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in PennyPerformers.com statements and opinions and such statements and opinions cannot be considered independent. PennyPerformers.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. PennyPerformers.com services are often paid for using free-trading shares. PennyPerformers.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
Visit us for a full Disclaimer at: www.PennyPerformers.com/disclaimer.htm
CONTACT: PennyPerformers.com
e-mail: info@pennyperformers.com
WWW: http://www.PennyPerformers.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
[ Back To TMCnet.com's Homepage ]
|
|
Discussions:
|
|
INDUSTRIES
Activate Email 
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO East, January 20-22, 2010. Miami, FL.
